DNA-cutting enzymes could slice through gene editing patent spat

Bang Wong, from source material provided by Feng Zhang

Who owns the biggest biotech advance of the century? Geneticists in Boston may have found a way around a high-stakes patent dispute over one of the most significant biotechnology breakthroughs in recent years, a gene-editing tool called CRISPR.

Read the full story in New Scientist.

Gene-Editing Startup Raises $120 Million to Apply CRISPR to Medicine

Editas Medicine, a company at the forefront of developing the gene-editing technology known as CRISPR, has raised $120 million to create new treatments for conditions including cancer, retinal disease, and sickle-cell anemia.

Monday’s announcement reflects a surge of interest in CRISPR, a technology that is only a few years old. It also serves to clarify the goals and strategy of Editas, which was founded by some of the most prominent inventors of the gene-editing system, including Feng Zhang, a researcher at the Broad Institute of Harvard and MIT.

Read the full article in MIT Technology Review.